HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

This article was originally published in The Rose Sheet

Executive Summary

L’Oreal/Lancome’s claims for Genifique anti-aging products, among others, identify the products as drugs under food and drug law, according to FDA’s Sept. 7 warning letter. Agency cites claims suggesting the brand’s technology “boosts the activity of genes” and “improve[s] the condition around the stem cells” – language that is not altogether unique in today’s anti-aging cosmeceutical market.

You may also be interested in...



FDA Clampdown On Excessive Anti-Aging Claims May Lighten Up In 2017

FDA issued close to 30 warning letters to cosmetics firms in 2016 for unapproved drug claims as part of “a project for reviewing product labels and websites for drug claims related to anti-aging.” That initiative may be winding down, if it hasn’t already, but the agency is playing its cards close to its vest going into the new year.

NAD: Anti-Aging Claims ‘Muted A Bit,’ But Vigilance Remains High

Anti-aging claims in the cosmetics sector show improved compliance with advertising standards overall, but the National Advertising Division remains on the lookout for potential overstatements, particularly as personal-care companies are less inclined to challenge each other than players in other industries.

Editorial: Will Next Anti-Aging Market Disruptor Be Anti-Anti-Aging?

"The Rose Sheet" makes a case for the theoretical Dollar Anti-Aging Club and why updating the FDCA's "cosmetic" definition as part of broader regulatory reform could be in industry's interest.

Related Content

Topics

UsernamePublicRestriction

Register

RS018280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel